XSHE
002262
Market cap3.32bUSD
Oct 09, Last price
21.74CNY
1D
-0.50%
1Q
9.03%
Jan 2017
66.43%
IPO
947.65%
Name
Jiangsu Nhwa Pharmaceutical Co Ltd
Chart & performance
P/E
20.89
P/S
3.78
EPS
1.04
Div yield, %
1.65%
Shrs. gr., 5y
-0.07%
Rev. gr., 5y
11.72%
Revenues
5.85b
+2.67%
Net income
1.06b
-7.54%
CFO
1.12b
+22.77%
Dividend
May 26, 20260.4 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiangsu Nhwa Pharmaceutical Co., LTD operates as a global pharmaceutical entity, focusing on the research, production, and sale of treatments for the central nervous system, along with cardiovascular and cerebrovascular ailments. Its comprehensive product line includes therapeutics for anesthesia, psychiatry, and neurological disorders. Additionally, the company is a supplier of Active Pharmaceutical Ingredients (APIs), specifically for central nervous system, anesthetic, and sedative applications, among others. The firm was established in 1978 and is based in Xuzhou, China.
Key people
Gangsheng Li
Chief Financial Officer · since 2022
Zengliang Chen
Deputy General Manager, Director · since 2007
Baozhou Duan
Deputy General Manager, Secretary of the Board · since 2013
Qing Fu
Deputy General Manager, Director · since 2007
Xinglei Jia
Staff Elected Director · since 2025
Jiaquan Sun
General Manager, Director · since 2019
Pengsheng Sun
Chairman of the Board · since 2007
Ziliang Yang
Deputy General Manager, Director · since 2007
Guoxiang Chen
Independent Director · since 2022
Xusheng Kong
Independent Director · since 2025
Yulan Li
Independent Director · since 2022
Xiaoxing Yin
Independent Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||